ME03557B - Privremena zaštiтa normalnih ćelija током hemoterapije - Google Patents

Privremena zaštiтa normalnih ćelija током hemoterapije

Info

Publication number
ME03557B
ME03557B MEP-2019-338A MEP2019338A ME03557B ME 03557 B ME03557 B ME 03557B ME P2019338 A MEP2019338 A ME P2019338A ME 03557 B ME03557 B ME 03557B
Authority
ME
Montenegro
Prior art keywords
normal cells
cells during
during chemotherapy
provisional protection
provisional
Prior art date
Application number
MEP-2019-338A
Other languages
German (de)
English (en)
French (fr)
Inventor
Jay Copeland Strum
John Emerson Bisi
Patrick Joseph Roberts
Francis Xavier Tavares
Original Assignee
G1 Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51527871&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ME03557(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by G1 Therapeutics Inc filed Critical G1 Therapeutics Inc
Publication of ME03557B publication Critical patent/ME03557B/me

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/527—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim spiro-condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
MEP-2019-338A 2013-03-15 2014-03-14 Privremena zaštiтa normalnih ćelija током hemoterapije ME03557B (me)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201361798772P 2013-03-15 2013-03-15
US201361861374P 2013-08-01 2013-08-01
US201361911354P 2013-12-03 2013-12-03
US201461949786P 2014-03-07 2014-03-07
EP14762438.1A EP2968290B1 (en) 2013-03-15 2014-03-14 Transient protection of normal cells during chemotherapy
PCT/US2014/028685 WO2014144326A1 (en) 2013-03-15 2014-03-14 Transient protection of normal cells during chemotherapy

Publications (1)

Publication Number Publication Date
ME03557B true ME03557B (me) 2020-07-20

Family

ID=51527871

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2019-338A ME03557B (me) 2013-03-15 2014-03-14 Privremena zaštiтa normalnih ćelija током hemoterapije

Country Status (18)

Country Link
US (15) US9527857B2 (me)
EP (4) EP2968291B1 (me)
JP (9) JP6430483B2 (me)
CN (4) CN108434149B (me)
CA (2) CA2906166C (me)
CY (1) CY1122434T1 (me)
DK (1) DK2968290T3 (me)
ES (2) ES2761406T3 (me)
HR (1) HRP20192168T1 (me)
HU (1) HUE046653T2 (me)
LT (1) LT2968290T (me)
ME (1) ME03557B (me)
PL (1) PL2968290T3 (me)
PT (1) PT2968290T (me)
RS (1) RS59790B1 (me)
SI (1) SI2968290T1 (me)
SM (1) SMT201900681T1 (me)
WO (2) WO2014144326A1 (me)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009061345A2 (en) 2007-11-07 2009-05-14 Cornell Research Foundation, Inc. Targeting cdk4 and cdk6 in cancer therapy
US8691830B2 (en) * 2010-10-25 2014-04-08 G1 Therapeutics, Inc. CDK inhibitors
EP2831080B1 (en) 2012-03-29 2017-03-15 Francis Xavier Tavares Lactam kinase inhibitors
CA2870019C (en) 2012-04-26 2020-08-18 Francis Xavier Tavares Synthesis of lactams
EP2967050A4 (en) 2013-03-15 2016-09-28 G1 Therapeutics Inc HIGH-ACTIVE ANTINEOPLASTIC AND ANTIPROLIFERATIVE AGENTS
EP2968291B1 (en) * 2013-03-15 2025-04-16 Pharmacosmos Holding A/S Hspc-sparing treatments for rb-positive abnormal cellular proliferation
US9717735B2 (en) 2014-04-17 2017-08-01 G1 Therapeutics, Inc. Tricyclic lactams for use in HSPC-sparing treatments for RB-positive abnormal cellular proliferation
WO2016040848A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
WO2016040858A1 (en) * 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Combinations and dosing regimes to treat rb-positive tumors
WO2016126889A1 (en) * 2015-02-03 2016-08-11 G1 Therapeutics, Inc. Cdk4/6 inhibitor dosage formulations for the protection of hematopoietic stem and progenitor cells during chemotherapy
HUE051898T2 (hu) * 2015-06-17 2021-03-29 Pfizer Triciklusos vegyületek és alkalmazásuk foszfodiészteráz inhibitorokként
EP3340986A1 (en) * 2015-08-28 2018-07-04 Novartis AG A pharmaceutical combination comprising the pi3k inhibitor alpelisib and the cdk4/6 inhibitor ribociclib, and the use thereof in the treatment/prevention of cancer
JP6635374B2 (ja) * 2015-12-18 2020-01-22 京都府公立大学法人 癌におけるリン酸化ｒｂタンパク質を指標としたイリノテカン感受性予測法
WO2017161253A1 (en) * 2016-03-18 2017-09-21 Tufts Medical Center Compositions and methods for treating and preventing metabolic disorders
CN114539273A (zh) 2016-06-07 2022-05-27 北京加科思新药研发有限公司 可用作shp2抑制剂的新型杂环衍生物
AU2017290362B2 (en) * 2016-07-01 2021-08-05 Pharmacosmos Holding A/S Synthesis of N-(heteroaryl)-pyrrolo[3,2-d]pyrimidin-2-amines
WO2018005533A1 (en) 2016-07-01 2018-01-04 G1 Therapeutics, Inc. Antiproliferative pyrimidine-based compounds
CA3028751A1 (en) * 2016-07-01 2018-01-04 G1 Therapeutics, Inc. Pyrimidine-based antiproliferative agents
WO2018005863A1 (en) 2016-07-01 2018-01-04 G1 Therapeutics, Inc. Pyrimidine-based compounds for the treatment of cancer
RU2769251C2 (ru) 2016-08-23 2022-03-29 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Комбинированная терапия для лечения гепатоцеллюлярной карциномы
WO2018089518A1 (en) 2016-11-08 2018-05-17 Dana-Farber Cancer Institute, Inc. Compositions and methods of modulating anti-tumor immunity
KR20240023677A (ko) 2016-12-05 2024-02-22 쥐원 쎄라퓨틱스, 인크. 화학요법 레지멘 동안의 면역 반응의 보존
AU2018205262A1 (en) * 2017-01-06 2019-07-11 G1 Therapeutics, Inc. Combination therapy for the treatment of cancer
US11395821B2 (en) 2017-01-30 2022-07-26 G1 Therapeutics, Inc. Treatment of EGFR-driven cancer with fewer side effects
EP3585389A4 (en) 2017-02-22 2020-12-23 G1 Therapeutics, Inc. EGFR-CAUSED CANCER TREATMENT WITH LESS SIDE EFFECTS
BR112019019261A2 (pt) 2017-03-16 2020-06-16 Eisai R & D Management Co., Ltd. Terapias de combinação para o tratamento de câncer de mama
HRP20241239T1 (hr) 2017-03-23 2024-12-06 Jacobio Pharmaceuticals Co., Ltd. Novi heterociklički derivati korisni kao shp2 inhibitori
MX392531B (es) 2017-06-29 2025-03-24 G1 Therapeutics Inc Formas morficas de g1t38 y metodos de preparacion de las mismas.
CN111094291B (zh) * 2017-08-11 2022-06-21 晟科药业（江苏）有限公司 1h-吡唑并[4,3-h]喹唑啉类化合物作为蛋白激酶抑制剂
WO2019136451A1 (en) 2018-01-08 2019-07-11 G1 Therapeutics, Inc. G1t38 superior dosage regimes
MA51846A (fr) 2018-02-15 2021-04-21 Nuvation Bio Inc Composés hétérocycliques utilisés en tant qu'inhibiteurs de kinases
CN112218634A (zh) * 2018-04-09 2021-01-12 G1治疗公司 具有驱动致癌突变的癌症的治疗
AU2019310595B2 (en) * 2018-07-27 2022-11-24 1200 Pharma Llc CDK inhibitors and uses thereof
CN120817904A (zh) 2018-08-24 2025-10-21 法码科思莫斯有限公司 1,4-二氮杂螺[5.5]十一烷-3-酮改进的合成
WO2020063760A1 (en) 2018-09-26 2020-04-02 Jacobio Pharmaceuticals Co., Ltd. Novel heterocyclic derivatives useful as shp2 inhibitors
WO2020097625A1 (en) * 2018-11-09 2020-05-14 G1 Therapeutics, Inc. Therapeutic regimens for treatment of cancer using eribulin and selective cdk4/6 inhibitor combinations
WO2020206035A1 (en) * 2019-04-01 2020-10-08 G1 Therapeutics, Inc. Treatment of cdk4/6 inhibitor resistant neoplastic disorders
AU2020296087A1 (en) * 2019-06-18 2022-01-27 Pharmacosmos Holding A/S Patient selection for enhancement of anti-tumor immunity in cancer patients
TW202128174A (zh) * 2019-10-09 2021-08-01 美商G1治療公司 失調之纖維母細胞生長因子受體訊息傳遞的癌症之標靶性治療
ES3048084T3 (en) 2020-05-19 2025-12-09 Pharmacosmos Holding As Cyclin-dependent kinase inhibiting compounds for the treatment of medical disorders
AU2021287380A1 (en) * 2020-06-11 2023-01-05 Lunella Biotech, Inc. Selective CDK4/6 inhibitor cancer therapeutics
US10988479B1 (en) 2020-06-15 2021-04-27 G1 Therapeutics, Inc. Morphic forms of trilaciclib and methods of manufacture thereof
CN116157403B (zh) * 2020-06-15 2025-04-25 海南先声再明医药股份有限公司 曲拉西利的形态及其制造方法
CN113788837B (zh) * 2021-08-02 2022-08-26 深圳湾实验室坪山生物医药研发转化中心 Trilaciclib的合成方法
WO2024073507A1 (en) 2022-09-28 2024-04-04 Theseus Pharmaceuticals, Inc. Macrocyclic compounds and uses thereof
WO2024116069A1 (en) * 2022-11-28 2024-06-06 Assia Chemical Industries Ltd. Novel trilaciclib intermediates, method of preparation and use thereof

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5591855A (en) 1994-10-14 1997-01-07 Cephalon, Inc. Fused pyrrolocarbazoles
US5628984A (en) 1995-07-31 1997-05-13 University Of North Carolina At Chapel Hill Method of detecting lung disease
ES2301194T3 (es) 1997-02-05 2008-06-16 Warner-Lambert Company Llc Pirido 2,3-d pirimidinas y 4-aminopirimidinas como inhibidores de la proliferacion celular.
GB9718913D0 (en) 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
US20040006074A1 (en) 1998-04-28 2004-01-08 The Government Of The United States Of America Cyclin dependent kinase (CDK)4 inhibitors and their use for treating cancer
AU778735B2 (en) 1998-06-16 2004-12-16 Centre National De La Recherche Scientifique Fused azepinone cyclin dependent kinase inhibitors
AU3584200A (en) 1999-01-29 2000-08-18 Board Of Trustees Of The University Of Illinois, The P53 inhibitors and therapeutic use of the same
US6958333B1 (en) 1999-07-26 2005-10-25 Banyu Pharmaceutical Co., Ltd. Biarylurea derivatives
US6387900B1 (en) 1999-08-12 2002-05-14 Pharmacia & Upjohn S.P.A. 3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents
US6291504B1 (en) 1999-10-20 2001-09-18 Dupont Pharmaceuticals Company Acylsemicarbazides and their uses
EP1242420A2 (en) 1999-12-16 2002-09-25 Eli Lilly And Company Agents and methods for the treatment of proliferative diseases
US7053070B2 (en) 2000-01-25 2006-05-30 Warner-Lambert Company Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors
CN100351253C (zh) 2000-06-26 2007-11-28 辉瑞产品公司 作为免疫抑制剂的吡咯并[2,3－d]嘧啶化合物
TR200401316T4 (tr) 2000-09-29 2004-07-21 Eli Lilly And Company Proliferatif hastalıkları tedavi etmek için yöntemler ve bileşikler
WO2002044174A2 (en) 2000-12-01 2002-06-06 Bristol-Myers Squibb Pharma Company 3-(2,4-dimethylthiazol-5-yl) indeno[1,2-c]pyrazol-4-one derivatives as cdk inhibitors
WO2002069892A2 (en) 2001-02-28 2002-09-12 Temple University Of The Commonwealth System Of Higher Education METHOD FOR PROTECTING CELLS AND TISSUES FROM IONIZING RADIATION TOXICITY WITH α, β UNSATURATED ARYL SULFONES
JP2004533449A (ja) 2001-05-11 2004-11-04 ボード　オブ　リージェンツ，　ザ　ユニバーシティ　オブ　テキサス　システム Ｃｄ２６を発現している細胞に関連する疾患の治療としての抗ｃｄ２６モノクローナル抗体
GEP20063909B (en) 2002-01-22 2006-08-25 Warner Lambert Co 2-(PYRIDIN-2-YLAMINO)-PYRIDO[2,3d] PYRIMIDIN-7-ONES
CA2495787A1 (en) 2002-05-01 2003-11-13 Chromos Molecular Systems, Inc. Methods for delivering nucleic acid molecules into cells and assessment thereof
JP2006516561A (ja) 2003-01-17 2006-07-06 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー 細胞増殖の阻害剤としての２−アミノピリジン置換ヘテロ環類
EA010904B1 (ru) 2003-05-22 2008-12-30 НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. Производные пиразолохиназолина: способ получения и применение в качестве ингибиторов киназ
ATE412650T1 (de) 2003-07-11 2008-11-15 Warner Lambert Co Isethionat salz eines selektiven cdk4 inhibitors
BRPI0415833A (pt) 2003-10-23 2007-01-02 Hoffmann La Roche derivados de triaza-espiropiperidina para uso como inibidores de glyt-1 no tratamento de distúrbios neurológicos e neuropsiquiátricos
GB0327380D0 (en) 2003-11-25 2003-12-31 Cyclacel Ltd Method
EP1740184A1 (en) 2004-03-30 2007-01-10 Pfizer Products Incorporated Combinations of signal transduction inhibitors
WO2005100999A2 (en) 2004-04-08 2005-10-27 Cornell Research Foundation, Inc. Functional immunohistochemical cell cycle analysis as a prognostic indicator for cancer
ITMI20040874A1 (it) 2004-04-30 2004-07-30 Ist Naz Stud Cura Dei Tumori Derivati indolici ed azaindolici con azione antitumorale
WO2005117908A2 (en) 2004-05-28 2005-12-15 Gemin X Biotechnologies, Inc. Triheterocyclic compounds compositions, and methods for treating cancer or viral diseases
WO2006074985A1 (en) 2005-01-14 2006-07-20 Janssen Pharmaceutica N.V. 5-membered annelated heterocyclic pyrimidines as kinase inhibitors
US20080161355A1 (en) 2005-01-21 2008-07-03 Astex Therapeutics Limited Combinations of Pyrazole Kinase Inhibitors and Further Antitumor Agents
EP1881983B1 (en) 2005-05-20 2012-01-11 Vertex Pharmaceuticals, Inc. Pyrrolopyridines useful as inhibitors of protein kinase
US20070049591A1 (en) 2005-08-25 2007-03-01 Kalypsys, Inc. Inhibitors of MAPK/Erk Kinase
EP1779848A1 (en) 2005-10-28 2007-05-02 Nikem Research S.R.L. V-ATPase inhibitors for the treatment of inflammatory and autoimmune diseases
ATE448230T1 (de) 2005-12-09 2009-11-15 Hoffmann La Roche Für die behandlung von obesitas geeignete tricyclische amidderivate
BRPI0620151A2 (pt) 2005-12-22 2010-06-29 Wyeth Corp composto; composição farmacêutica; método de tratar ou inibir o crescimento de células tumorais cancerosas em um mamìfero que deste necessita; método; e processo
EP2591775A1 (en) 2006-04-05 2013-05-15 Novartis AG Combinations comprising mtor inhibitors for treating cancer
US20070270362A1 (en) 2006-05-18 2007-11-22 The University Of Washington Methods and compositions for prevention or treatment of inflammatory-related diseases and disorders
CA2656290A1 (en) 2006-07-05 2008-01-10 Exelixis, Inc. Methods of using igf1r and abl kinase modulators
EP2061469B8 (en) 2006-09-11 2014-02-26 Curis, Inc. Quinazoline based egfr inhibitors
AU2007333791A1 (en) 2006-12-14 2008-06-26 Panacea Pharmaceuticals, Inc. Methods of neuroprotection by cyclin-dependent kinase inhibition
AU2007336933A1 (en) 2006-12-22 2008-07-03 Novartis Ag Heteroaryl-heteroaryl compounds as CDK inhibitors for the treatment of cancer, inflammation and viral infections
US20110002855A1 (en) 2007-06-25 2011-01-06 Neurogen Corporation Piperazinyl oxoalkyl tetrahydro-beta-carbolines and related analogues
WO2009061345A2 (en) 2007-11-07 2009-05-14 Cornell Research Foundation, Inc. Targeting cdk4 and cdk6 in cancer therapy
MX2010006457A (es) 2007-12-19 2010-07-05 Amgen Inc Compuestos fusionados de piridina, pirimidina y triazina como inhibidores de ciclo celular.
WO2010012777A1 (en) 2008-07-29 2010-02-04 Nerviano Medical Sciences S.R.L. THERAPEUTIC COMBINATION COMPRISING A CDKs INHIBITOR AND AN ANTINEOPLASTIC AGENT
CN102186856B (zh) 2008-08-22 2014-09-24 诺华股份有限公司 作为cdk抑制剂的吡咯并嘧啶化合物
EP2341906A4 (en) * 2008-10-01 2012-06-13 Univ North Carolina HEMATOPOIETIC PROTECTION AGAINST IONIZATION RADIATION USING SELF-ACTIVE CYCLINE-DEPENDENT KINASE-4/6-HEMMER
AU2009298367A1 (en) 2008-10-01 2010-04-08 The University Of North Carolina At Chapel Hill Hematopoietic protection against chemotherapeutic compounds using selective cyclin-dependent kinase 4/6 inhibitors
JO2885B1 (en) 2008-12-22 2015-03-15 ايلي ليلي اند كومباني Protein kinase inhibitors
EP3406260B1 (en) 2009-05-13 2020-09-23 The University of North Carolina at Chapel Hill Cyclin dependent kinase inhibitors and methods of use
WO2011103485A1 (en) 2010-02-18 2011-08-25 Medivation Technologies, Inc. Fused tetracyclic pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use
UY33227A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
UY33226A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina deuterada como inhibidores de la cdk4/6
FR2957748B1 (fr) * 2010-03-16 2012-09-07 St Microelectronics Grenoble 2 Composant electronique a montage en surface
CN102299073A (zh) 2010-06-25 2011-12-28 无锡华润上华半导体有限公司 Vdmos器件及其制作方法
SG10201508715YA (en) 2010-10-25 2015-11-27 G1 Therapeutics Inc Cdk inhibitors
US8691830B2 (en) * 2010-10-25 2014-04-08 G1 Therapeutics, Inc. CDK inhibitors
DK2635583T3 (en) 2010-11-02 2015-08-03 Promega Corp Coelenterazinderivater and methods of use thereof
WO2012068381A2 (en) 2010-11-17 2012-05-24 The University Of North Carolina At Chapel Hill Protection of renal tissues from schema through inhibition of the proliferative kisses cdk4 and cdk6
EP2655375B1 (fr) 2010-12-23 2014-12-03 Sanofi Derives de pyrimidinone, leur preparation et leur utilisation pharmaceutique
DK2688887T3 (en) 2011-03-23 2015-06-29 Amgen Inc DEHYDRATED tricyclic DUALINHIBITORER OF CDK 4/6 AND FLT3
TW201733984A (zh) 2011-04-13 2017-10-01 雅酶股份有限公司 經取代之苯化合物
AU2012279117A1 (en) 2011-07-01 2014-01-09 Novartis Ag Combination therapy comprising a CDK4/6 inhibitor and a PI3K inhibitor for use in the treatment of cancer
ES2654177T3 (es) 2011-07-27 2018-02-12 Astrazeneca Ab Derivados de 2-(2,4,5-anilino sustituido)pirimidina como moduladores de EGFR útiles para tratar el cáncer
EP2831080B1 (en) 2012-03-29 2017-03-15 Francis Xavier Tavares Lactam kinase inhibitors
CA2870019C (en) 2012-04-26 2020-08-18 Francis Xavier Tavares Synthesis of lactams
HK1213044A1 (zh) 2012-08-03 2016-06-24 Foundation Medicine, Inc. 人乳头瘤病毒作为肿瘤预後的预测因子
US9241941B2 (en) 2012-09-20 2016-01-26 Memorial Sloan-Kettering Cancer Center Methods for treatment of lymphomas with mutations in cell cycle genes
EP2925365A1 (en) 2012-11-28 2015-10-07 Novartis AG Combination therapy
US20140274896A1 (en) 2013-03-15 2014-09-18 G1 Therapeutics, Inc. Transient Protection of Hematopoietic Stem and Progenitor Cells Against Ionizing Radiation
EP2967050A4 (en) * 2013-03-15 2016-09-28 G1 Therapeutics Inc HIGH-ACTIVE ANTINEOPLASTIC AND ANTIPROLIFERATIVE AGENTS
EP2968291B1 (en) * 2013-03-15 2025-04-16 Pharmacosmos Holding A/S Hspc-sparing treatments for rb-positive abnormal cellular proliferation
BR112015025711A8 (pt) 2013-04-08 2019-12-17 Janssen Pharmaceutica Nv uso de ibrutinibe e coposição farmacêutica compreendendo ibrutinibe e um agente anticâncer
EP3003309B1 (en) 2013-05-30 2020-09-09 Infinity Pharmaceuticals, Inc. Treatment of cancers using pi3 kinase isoform modulators
WO2015061407A1 (en) 2013-10-24 2015-04-30 Francis Xavier Tavares Process for synthesis of lactams
US10314842B2 (en) 2013-12-02 2019-06-11 Cornell University Methods for treating B cell proliferative disorders
ES2687477T3 (es) 2013-12-31 2018-10-25 Xuanzhu Pharma Co., Ltd. Inhibidor de quinasa y su uso
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
US9717735B2 (en) 2014-04-17 2017-08-01 G1 Therapeutics, Inc. Tricyclic lactams for use in HSPC-sparing treatments for RB-positive abnormal cellular proliferation
WO2016040848A1 (en) * 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
WO2016040858A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Combinations and dosing regimes to treat rb-positive tumors
US9374037B2 (en) 2014-10-30 2016-06-21 M/A-Com Technology Solutions Holdings, Inc. Voltage-controlled oscillator with mask-selectable performance
WO2016126889A1 (en) 2015-02-03 2016-08-11 G1 Therapeutics, Inc. Cdk4/6 inhibitor dosage formulations for the protection of hematopoietic stem and progenitor cells during chemotherapy
AU2017290362B2 (en) * 2016-07-01 2021-08-05 Pharmacosmos Holding A/S Synthesis of N-(heteroaryl)-pyrrolo[3,2-d]pyrimidin-2-amines
WO2018005863A1 (en) 2016-07-01 2018-01-04 G1 Therapeutics, Inc. Pyrimidine-based compounds for the treatment of cancer
KR20240023677A (ko) * 2016-12-05 2024-02-22 쥐원 쎄라퓨틱스, 인크. 화학요법 레지멘 동안의 면역 반응의 보존
EP3551185A4 (en) * 2016-12-08 2021-07-14 Icahn School of Medicine at Mount Sinai COMPOSITIONS AND METHODS OF TREATMENT OF CDK4 / 6 MEDIATED CANCER
AU2018205262A1 (en) * 2017-01-06 2019-07-11 G1 Therapeutics, Inc. Combination therapy for the treatment of cancer
US11395821B2 (en) * 2017-01-30 2022-07-26 G1 Therapeutics, Inc. Treatment of EGFR-driven cancer with fewer side effects
EP3580223A4 (en) * 2017-02-10 2021-01-06 G1 Therapeutics, Inc. Benzothiophene estrogen receptor modulators
EP3585389A4 (en) * 2017-02-22 2020-12-23 G1 Therapeutics, Inc. EGFR-CAUSED CANCER TREATMENT WITH LESS SIDE EFFECTS
MX392531B (es) * 2017-06-29 2025-03-24 G1 Therapeutics Inc Formas morficas de g1t38 y metodos de preparacion de las mismas.
WO2019136244A1 (en) 2018-01-04 2019-07-11 G1 Therapeutics, Inc. Heterocyclic compounds for the treatment of abnormal cellular proliferation
WO2019136451A1 (en) * 2018-01-08 2019-07-11 G1 Therapeutics, Inc. G1t38 superior dosage regimes
CN112218634A (zh) * 2018-04-09 2021-01-12 G1治疗公司 具有驱动致癌突变的癌症的治疗
WO2020023502A1 (en) * 2018-07-23 2020-01-30 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
AU2020296087A1 (en) * 2019-06-18 2022-01-27 Pharmacosmos Holding A/S Patient selection for enhancement of anti-tumor immunity in cancer patients
TW202128174A (zh) * 2019-10-09 2021-08-01 美商G1治療公司 失調之纖維母細胞生長因子受體訊息傳遞的癌症之標靶性治療

Also Published As

Publication number Publication date
WO2014144326A1 (en) 2014-09-18
US20180221378A1 (en) 2018-08-09
US11040042B2 (en) 2021-06-22
US20230381189A1 (en) 2023-11-30
HRP20192168T1 (hr) 2020-02-21
EP4596051A3 (en) 2025-10-29
JP6337083B2 (ja) 2018-06-06
HUE046653T2 (hu) 2020-03-30
US20170065597A1 (en) 2017-03-09
JP2021001197A (ja) 2021-01-07
US9931345B2 (en) 2018-04-03
US20190070185A1 (en) 2019-03-07
JP2018150333A (ja) 2018-09-27
CN108434149A (zh) 2018-08-24
US10434104B2 (en) 2019-10-08
EP2968290A4 (en) 2016-09-28
WO2014144847A2 (en) 2014-09-18
US11654148B2 (en) 2023-05-23
US20180360840A1 (en) 2018-12-20
US20170100405A1 (en) 2017-04-13
CN108283644B (zh) 2022-03-18
US11717523B2 (en) 2023-08-08
EP3653209A1 (en) 2020-05-20
US20140275067A1 (en) 2014-09-18
JP2023078341A (ja) 2023-06-06
US9487530B2 (en) 2016-11-08
US10076523B2 (en) 2018-09-18
HK1222792A1 (zh) 2017-07-14
EP2968290B1 (en) 2019-09-25
US20180360841A1 (en) 2018-12-20
CN105407889A (zh) 2016-03-16
RS59790B1 (sr) 2020-02-28
US9464092B2 (en) 2016-10-11
US10925878B2 (en) 2021-02-23
CA2906156C (en) 2023-03-14
SI2968290T1 (sl) 2020-02-28
HK1223293A1 (zh) 2017-07-28
JP2023052449A (ja) 2023-04-11
DK2968290T3 (da) 2019-11-25
CA2906166A1 (en) 2014-09-18
US20140275066A1 (en) 2014-09-18
US9527857B2 (en) 2016-12-27
US10660896B2 (en) 2020-05-26
US20210213022A1 (en) 2021-07-15
US20230364098A1 (en) 2023-11-16
EP2968291C0 (en) 2025-04-16
WO2014144847A3 (en) 2015-07-02
JP2016514689A (ja) 2016-05-23
JP2019055954A (ja) 2019-04-11
US20170037051A1 (en) 2017-02-09
US20140271466A1 (en) 2014-09-18
ES3032492T3 (en) 2025-07-21
JP6738933B6 (ja) 2020-09-09
PL2968290T3 (pl) 2020-04-30
CY1122434T1 (el) 2021-01-27
CN108434149B (zh) 2021-05-28
PT2968290T (pt) 2019-11-27
JP7250737B2 (ja) 2023-04-03
CN105407889B (zh) 2018-06-01
CA2906166C (en) 2023-03-14
SMT201900681T1 (it) 2020-01-14
EP2968291A4 (en) 2016-09-28
EP4596051A2 (en) 2025-08-06
LT2968290T (lt) 2019-12-10
EP2968290A1 (en) 2016-01-20
EP2968291B1 (en) 2025-04-16
EP2968291A2 (en) 2016-01-20
JP7213854B2 (ja) 2023-01-27
CN108283644A (zh) 2018-07-17
JP6738933B2 (ja) 2020-08-12
JP2019131609A (ja) 2019-08-08
JP6517401B2 (ja) 2019-05-22
CN105473140B (zh) 2018-04-10
US10966984B2 (en) 2021-04-06
JP2016513737A (ja) 2016-05-16
CN105473140A (zh) 2016-04-06
JP6767456B2 (ja) 2020-10-14
JP2020183422A (ja) 2020-11-12
US20210299130A1 (en) 2021-09-30
HK1258477A1 (zh) 2019-11-15
US20200345742A1 (en) 2020-11-05
ES2761406T3 (es) 2020-05-19
CA2906156A1 (en) 2014-09-18
JP6430483B2 (ja) 2018-11-28
US10085992B2 (en) 2018-10-02

Similar Documents

Publication Publication Date Title
ME03557B (me) Privremena zaštiтa normalnih ćelija током hemoterapije
IL245573B (en) Cell
DK3461491T3 (da) Forbedret adoptiv celleterapi
LT3290407T (lt) Bromodomeno inhibitoriai
EP2969007A4 (en) HISTONE DEMETHYLASE INHIBITORS
PL2978419T3 (pl) Kompozycje do zwiększania żywotności komórek i metody ich stosowania
EP2889350A4 (en) ADHESIVE COMPOSITION
DK2941483T3 (da) Fremgangsmåde til at opnå immunstimulerende dendritriske celler
FR3003076B1 (fr) Supercondensateur electrochimique
DK3027750T3 (da) Biokatalytisk sammensætning
DOS2013000177S (es) Capsulas
PL3388426T3 (pl) Związki do ochrony komórek
PL3030519T3 (pl) Trójpierścieniowe związki benzoksaborolu i ich zastosowania
DK3060038T3 (da) Beskyttelseskasse til frø
BR112015020275A2 (pt) estrutura flutuante
DE112014004791A5 (de) Hochwasserschutz
TWM475821U (en) Structure of mosquito-catch
TH1601002376B (th) โครงสร้างการคุ้มกันแบตเตอรี่
FI10242U1 (fi) Vuotosuoja
TH1501000004B (th) โครงสร้างสำหรับการป้องกันการจมน้ำของอุปกรณ์
FI10671U1 (fi) Eristyselementti
ITPN20130028U1 (it) Struttura di protezione per pareti
DK3082855T3 (da) Sammensætning
UA26756S (uk) Гідророзподільник
TWM475524U (en) Structure of rivet-pulling